Already have an account? Sign-in to get started.

Moving Forward from the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize Outcomes

Overview

To view this online CME activity and complete the pre/posttests and evaluation, please CLICK "VIEW ACTIVITY" BUTTON UNDER STEP 1.

Or CLICK  the following link:  http://www.gotoper.com/online-cme-activities/cpc/moving-forward-from-the-status-quo-for-the-treatment-of-soft-tissue-sarcoma-key-questions--new-answers-to-optimize-outcomes

Activity Overview:  Are you prepared to provide state-of-the-art care to the next patient who presents to your clinic with a soft tissue sarcoma (STS)? Don’t miss this opportunity to hear renowned experts discuss the current standard of care and provide insights into the evolving approaches and breakthroughs occurring in the field of STS.

Historically poor outcomes in patients with metastatic STS have led to therapeutic nihilism among some physicians. However, a greater appreciation of the heterogeneous, complex biologies across the many STS subtypes, as well as the development of new and emerging therapeutic approaches, are transforming the ways in which these malignancies are managed. Optimal treatment requires a highly skilled, multidisciplinary team that encompasses medicine, pathology, radiology, and surgery.

Target Audience:  This educational activity is directed toward medical, surgical, and radiation oncologists, as well as fellows, who manage patients with STS. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with STS may also participate.

 

Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Detail methods to engage community-based oncologists to communicate with sarcoma specialists in the care of patients with STS in multiple lines of treatment
  2. Evaluate clinical circumstances that impact sequencing decision making along the disease continuum in the management of STS
  3. Explain disease heterogeneity in advanced STS, and its impact on treatment strategies and methods to overcome challenges to optimize diagnoses in the field
  4. Describe novel mechanistic approaches that have been applied to the treatment of patients with metastatic or unresectable STS

Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Physicians Education Resource, LLC'. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Your Status

STEP
1

Comments

People have also taken...

Rating